Table 3: Pharmacokinetics parameters obtained following oral administration of marketed capsules and the test to rabbits (mean ± SD, n = 3).
| Parameters | Marketed tablets | Test |
| Tmax (min) | 30 | 23.33 ± 5.77 |
| Cmax (ng/mL) | 476.13 ± 44.84 | 686.06 ± 69.94* |
| t1/2 (min) | 44.11 ± 1.79 | 52.41 ± 8.45 |
| AUC0-τ (min•ng/mL) | 39011.55 ± 6637.08 | 54180.11 ± 6483.16* |
| MRT0-τ (min) | 78.48 ± 3.88 | 75.51 ± 1.16 |
| Relative bioavailability (%) | 100 | 138.88 |
*p < 0.05 vs. marketed capsules.